Key result
Cilazapril monotherapy is linked to BP control in ~68% of patients, but added chlorthalidone offsets lipid benefits.
Why the study?
Does cilazapril treatment improve serum lipids and fibrinogen in hypertensive patients?
Observational (n=114)
Yes
Does cilazapril treatment improve serum lipids and fibrinogen in hypertensive patients?
Cilazapril monotherapy improves lipid profiles and fibrinogen in hypertensive patients, but adding a diuretic like chlorthalidone reverses these metabolic benefits.
No takes yet. Share an insight, caveat, or question.
Cilazapril monotherapy may confer metabolic benefits in hypertension; this observational finding leaves open confirmation and clinical relevance in randomized trials.
Tsagadopoulos et al. (2008) conducted an observational in hypertension (n=114). Cilazapril vs. Cilazapril plus chlorthalidone was evaluated on serum lipids and fibrinogen. Cilazapril monotherapy achieved satisfactory blood pressure control in 68% of patients and improved lipid profiles and fibrinogen, but adding chlorthalidone reversed the lipid/fibrinogen benefits.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: